ORAL C5A RECEPTOR ANTAGONIST CCX168 PHASE 2 CLINICAL TRIAL IN ANCA-ASSOCIATED RENAL VASCULITIS

被引：7

作者：

Jayne, D. R. ^{[1
]}

Bruchfeld, A. ^{[2
]}

Schaier, M. ^{[3
]}

Ciechanowski, K. ^{[4
]}

Harper, L. ^{[5
]}

Jadoul, M. ^{[6
]}

Segelmark, M. ^{[7
]}

Selga, D. ^{[8
]}

Szombati, I. ^{[9
]}

Venning, M. ^{[10
]}

Hugo, C. ^{[11
]}

Van Daele, P. L. ^{[12
]}

Viklicky, O. ^{[13
]}

Potarca, A. ^{[14
]}

Schall, T. J. ^{[14
]}

Bekker, P. ^{[14
]}

机构：

[1] Univ Cambridge, Cambridge, England

[2] Karolinska Inst, Stockholm, Sweden

[3] Univ Heidelberg Hosp, Heidelberg, Germany

[4] Pomeranian Med Univ, Szczecin, Poland

[5] Univ Birmingham, Birmingham, W Midlands, England

[6] Clin St Luc, Brussels, Belgium

[7] Linkoping Univ, Linkoping, Sweden

[8] Lund Univ, Lund, Sweden

[9] Budaclin, Budapest, Hungary

[10] Univ Manchester, Manchester, Lancs, England

[11] Univ Manchester, Manchester, Lancs, England

[12] Erasmus Sch Ctr, Rotterdam, Netherlands

[13] Inst Clin Exp Med, Prague, Czech Republic

[14] ChemoCentryx Inc, Mountain View, CA USA

来源：

关键词：

D O I：

10.1136/annrheumdis-2014-eular.3728

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

OP0227

引用

页码：148 / 148

页数：1